Search

Your search keyword '"MESH : Bone Neoplasms"' showing total 3 results
Start Over Descriptor "MESH : Bone Neoplasms" Topic 030304 developmental biology
3 results on '"MESH : Bone Neoplasms"'

1. EWS-FLI1 inhibits TNFα-induced NFκB-dependent transcription in Ewing sarcoma cells

Author

Christian Auclair, Franck Tirode, Olivier Delattre, Alain Lilienbaum, Julie Lagirand-Cantaloube, Marie-Hélène Kryszke, Karine Laud, Laboratoire de Biologie et de Pharmacologie Appliquée (LBPA), École normale supérieure - Cachan (ENS Cachan)-Centre National de la Recherche Scientifique (CNRS), Centre de recherches de biochimie macromoléculaire (CRBM), Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-IFR122-Centre National de la Recherche Scientifique (CNRS), Unité de génétique et biologie des cancers (U830), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie-Institut National de la Santé et de la Recherche Médicale (INSERM), Stress et pathologies du cytosquelette EA 300, Université Paris Diderot - Paris 7 (UPD7), Centre de recherche en Biologie Cellulaire (CRBM), Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biologie et de Pharmacologie Appliquée ( LBPA ), École normale supérieure - Cachan ( ENS Cachan ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de recherches de biochimie macromoléculaire ( CRBM ), Université Montpellier 1 ( UM1 ) -Université Montpellier 2 - Sciences et Techniques ( UM2 ) -IFR122-Centre National de la Recherche Scientifique ( CNRS ), Unité de génétique et biologie des cancers ( U830 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut Curie-Institut National de la Santé et de la Recherche Médicale ( INSERM ), and Université Paris Diderot - Paris 7 ( UPD7 )

Subjects
Oncogene Proteins, Fusion, Transcription, Genetic, Electrophoretic Mobility Shift Assay, MESH : Oncogene Proteins, Fusion, medicine.disease_cause, Biochemistry, 0302 clinical medicine, MESH: Transcription Factor RelA, Genes, Reporter, Transcription (biology), Gene expression, Luciferases, MESH : Tumor Necrosis Factor-alpha, 0303 health sciences, Gene knockdown, MESH: Proto-Oncogene Protein c-fli-1, MESH: Gene Expression Regulation, Neoplastic, MESH : Genes, Reporter, MESH: Bone Neoplasms, Gene Expression Regulation, Neoplastic, MESH: Sarcoma, Ewing's, MESH : Sarcoma, Ewing's, MESH : Electrophoretic Mobility Shift Assay, 030220 oncology & carcinogenesis, Tumor necrosis factor alpha, MESH: Cell Line, Tumor, MESH : Gene Expression Regulation, Neoplastic, Biophysics, Bone Neoplasms, Sarcoma, Ewing, Biology, 03 medical and health sciences, Cell Line, Tumor, medicine, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, [ SDV.BBM ] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Molecular Biology, Transcription factor, MESH : Bone Neoplasms, 030304 developmental biology, MESH : Luciferases, MESH: Humans, Proto-Oncogene Protein c-fli-1, Tumor Necrosis Factor-alpha, MESH : Cell Line, Tumor, MESH: Transcription, Genetic, MESH : Transcription Factor RelA, MESH : Humans, MESH: Genes, Reporter, fungi, Transcription Factor RelA, MESH : Transcription, Genetic, Promoter, Cell Biology, Fusion protein, MESH : Proto-Oncogene Protein c-fli-1, MESH: Tumor Necrosis Factor-alpha, MESH: Electrophoretic Mobility Shift Assay, Cancer research, MESH: Luciferases, RNA-Binding Protein EWS, Carcinogenesis, MESH: Oncogene Proteins, Fusion
Abstract

International audience; Ewing sarcoma is primarily caused by a t(11;22) chromosomal translocation encoding the EWS-FLI1 fusion protein. To exert its oncogenic function, EWS-FLI1 acts as an aberrant transcription factor, broadly altering the gene expression profile of tumor cells. Nuclear factor-kappaB (NFkappaB) is a tightly regulated transcription factor controlling cell survival, proliferation and differentiation, as well as tumorigenesis. NFkappaB activity is very low in unstimulated Ewing sarcoma cells, but can be induced in response to tumor necrosis factor (TNF). We wondered whether NFkappaB activity could be modulated by EWS-FLI1 in Ewing sarcoma. Using a knockdown approach in Ewing sarcoma cells, we demonstrated that EWS-FLI1 has no influence on NFkappaB basal activity, but impairs TNF-induced NFkappaB-driven transcription, at least in part through inhibition of NFkappaB binding to DNA. We detected an in vivo physical interaction between the fusion protein and NFkappaB p65, which could mediate these effects. Our findings suggest that, besides directly controlling the activity of its primary target promoters, EWS-FLI1 can also indirectly influence gene expression in tumor cells by modulating the activity of key transcription factors such as NFkappaB.

Published
2010
Full Text
View/download PDF

2. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

Author

John W. Loewy, George D. Demetri, Lori Berk, Laurence H. Baker, Victor M. Rivera, Arthur P. Staddon, Gina Z. D'Amato, Tim Clackson, Monica M. Mita, Kamalesh Kumar Sankhala, Frank G. Haluska, Scott M. Schuetze, Jean-Yves Blay, Anthony W. Tolcher, Sant P. Chawla, International Institute of Clinical Studies, Pennsylvania Oncology Hematology Associates, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard [Lyon], Department of Cancer Biology, Dana-Farber Cancer Institute [Boston], Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), and Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
Male, Vascular Endothelial Growth Factor A, Oncology, Cancer Research, Pathology, MESH : Aged, Phases of clinical research, Kaplan-Meier Estimate, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, chemistry.chemical_compound, 0302 clinical medicine, MESH : Tumor Markers, Biological, Clinical endpoint, Medicine, MESH : Female, Infusions, Intravenous, MESH: Treatment Outcome, MESH: Aged, 0303 health sciences, education.field_of_study, MESH: Middle Aged, TOR Serine-Threonine Kinases, Soft tissue, Sarcoma, MESH : Infusions, Intravenous, Middle Aged, MESH : Adult, MESH: Bone Neoplasms, 3. Good health, MESH : Antineoplastic Agents, Treatment Outcome, 030220 oncology & carcinogenesis, MESH : Vascular Endothelial Growth Factor A, MESH : TOR Serine-Threonine Kinases, MESH : Disease-Free Survival, Female, Adult, medicine.medical_specialty, MESH : Male, MESH : Sex Factors, Population, MESH : Drug Administration Schedule, Antineoplastic Agents, Bone Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, Bone Sarcoma, MESH: Drug Administration Schedule, MESH : Sarcoma, Disease-Free Survival, Drug Administration Schedule, Ridaforolimus, MESH : Kaplan-Meier Estimate, 03 medical and health sciences, Sex Factors, MESH: Sex Factors, Internal medicine, Biomarkers, Tumor, Humans, MESH : Middle Aged, education, MESH: Infusions, Intravenous, MESH: TOR Serine-Threonine Kinases, MESH: Kaplan-Meier Estimate, Aged, 030304 developmental biology, MESH : Bone Neoplasms, Sirolimus, MESH: Humans, Errata, Akt/PKB signaling pathway, business.industry, MESH : Sirolimus, MESH: Vascular Endothelial Growth Factor A, MESH : Humans, MESH: Adult, MESH: Male, Clinical trial, chemistry, MESH: Sarcoma, MESH: Tumor Markers, Biological, MESH: Disease-Free Survival, MESH: Antineoplastic Agents, MESH: Sirolimus, business, MESH: Female
Abstract

Purpose Ridaforolimus is an inhibitor of mammalian target of rapamycin, an integral component of the phosphatidyl 3-kinase/AKT signaling pathway, with early evidence of activity in sarcomas. This multicenter, open-label, single-arm, phase II trial was conducted to assess the antitumor activity of ridaforolimus in patients with distinct subtypes of advanced sarcomas. Patients and Methods Patients with metastatic or unresectable soft tissue or bone sarcomas received ridaforolimus 12.5 mg administered as a 30-minute intravenous infusion once daily for 5 days every 2 weeks. The primary end point was clinical benefit response (CBR) rate (complete response or partial response [PR] or stable disease ≥ 16 weeks). Safety, progression-free survival (PFS), overall survival (OS), time to progression, and duration of response were also evaluated. Results A total of 212 patients were treated in four separate histologic cohorts. In this heavily pretreated population, 61 patients (28.8%) achieved CBR. Median PFS was 15.3 weeks; median OS was 40 weeks. Response Evaluation Criteria in Solid Tumors (RECIST) confirmed response rate was 1.9%, with four patients achieving confirmed PR (two with osteosarcoma, one with spindle cell sarcoma, and one with malignant fibrous histiocytoma). Archival tumor protein markers analyzed were not correlated with CBR. Related adverse events were generally mild or moderate and consisted primarily of stomatitis, mucosal inflammation, mouth ulceration, rash, and fatigue. Conclusion Single-agent ridaforolimus in patients with advanced and pretreated sarcomas led to PFS results that compare favorably with historical metrics. A phase III trial based on these data will further define ridaforolimus activity in sarcomas.

Published
2012
Full Text
View/download PDF

3. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

Author

Pierre-Paul Bringuier, Christophe Bergeron, Luc Istier, Laurent Alberti, Philippe Chalabreysse, A. Lurkin, Dominic Cellier, Michel Peoc'h, Françoise Ducimetière, Jean-Yves Blay, Isabelle Ray-Coquard, Anne-Valérie Decouvelaere, Anne-Marie Schott, Dominique Ranchère-Vince, Christine B. Müller, Jean-Yves Scoazec, Département d'Oncologie Médicale, Centre Léon Bérard [Lyon]-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Santé-Individu-Société 'SIS', Centre Léon Bérard [Lyon], Département d'anatomopathologie, biopathologie, Biologie, Ingénierie et Imagerie de la Greffe de Cornée ( EA 2521, JE2521, IFR143 ), Université Jean Monnet [Saint-Étienne] ( UJM ), Institute of Functional Interfaces, Karlsruhe Institute of Technology ( KIT ), Equipe 11, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Equipe 4, equipe 4, Laboratoire Central d'Anatomie et de Cytologie Pathologiques [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ) -Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ) -Centre de Recherche en Cancérologie de Lyon ( CRCL ), Département d'information médicale, Hospices Civils de Lyon ( HCL ) -Université de Lyon, Service d'Oncologie, Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] ( IHOPe ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Merck Serono, Parcours santé systémique (P2S), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Biologie, Ingénierie et Imagerie pour l'Ophtalmologie (BIIO), Université Jean Monnet - Saint-Étienne (UJM), Karlsruhe Institute of Technology (KIT), Oncogénèse et progression tumorale, Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL)-Université de Lyon, Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Merck & Co. Inc, Santé Individu Société (SIS), Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biologie, Ingénierie et Imagerie de la Greffe de Cornée (EA 2521, JE2521, IFR143), Université Jean Monnet [Saint-Étienne] (UJM), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Santé Individu Société - SIS (SIS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Moulin - Lyon 3 (UJML), and Université de Lyon-Université Lumière - Lyon 2 (UL2)

Subjects
Male, Pathology, Epidemiology, MESH : Prospective Studies, MESH : Aged, Soft Tissue Neoplasms, MESH : Sarcoma, Kaposi, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH : Female, Prospective Studies, MESH: Incidence, Prospective cohort study, MESH: Aged, 0303 health sciences, education.field_of_study, MESH: Middle Aged, MESH: Epidemiologic Studies, Multidisciplinary, Incidence, Incidence (epidemiology), Sarcoma, Middle Aged, MESH : Adult, MESH: Bone Neoplasms, MESH : Incidence, 3. Good health, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Medicine, Female, Cancer Epidemiology, Research Article, MESH: Soft Tissue Neoplasms, Adult, Leiomyosarcoma, medicine.medical_specialty, Adolescent, MESH : Male, Science, Population, MESH : Young Adult, Bone Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Liposarcoma, Bone Sarcoma, MESH : Sarcoma, MESH : Epidemiologic Studies, Young Adult, 03 medical and health sciences, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, education, Sarcoma, Kaposi, Aged, 030304 developmental biology, MESH : Bone Neoplasms, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Epidemiologic Studies, MESH: Sarcoma, MESH: Sarcoma, Kaposi, business, MESH: Female, MESH : Soft Tissue Neoplasms
Abstract

International audience; BACKGROUND: The exact overall incidence of sarcoma and sarcoma subtypes is not known. The objective of the present population-based study was to determine this incidence in a European region (Rhone-Alpes) of six million inhabitants, based on a central pathological review of the cases. METHODOLOGY/PRINCIPAL FINDINGS: From March 2005 to February 2007, pathology reports and tumor blocks were prospectively collected from the 158 pathologists of the Rhone-Alpes region. All diagnosed or suspected cases of sarcoma were collected, reviewed centrally, examined for molecular alterations and classified according to the 2002 World Health Organization classification. Of the 1287 patients screened during the study period, 748 met the criteria for inclusion in the study. The overall crude and world age-standardized incidence rates were respectively 6.2 and 4.8 per 100,000/year. Incidence rates for soft tissue, visceral and bone sarcomas were respectively 3.6, 2.0 and 0.6 per 100,000. The most frequent histological subtypes were gastrointestinal stromal tumor (18%; 1.1/100,000), unclassified sarcoma (16%; 1/100,000), liposarcoma (15%; 0.9/100,000) and leiomyosarcoma (11%; 0.7/100,000). CONCLUSIONS/SIGNIFICANCE: The observed incidence of sarcomas was higher than expected. This study is the first detailed investigation of the crude incidence of histological and molecular subtypes of sarcomas.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results